Pelaez Coyotl 2020 Pharmaceutics: Difference between revisions

From Bioblast
No edit summary
No edit summary
Β 
(2 intermediate revisions by the same user not shown)
Line 8: Line 8:
|keywords=Antimicrobial peptide, Autophagy, Iztli peptide, Multidrug resistant, Tuberculosis
|keywords=Antimicrobial peptide, Autophagy, Iztli peptide, Multidrug resistant, Tuberculosis
|editor=[[Plangger M]]
|editor=[[Plangger M]]
|mipnetlab=MX Mexico City Uribe-Carvajal S
}}
}}
{{Labeling
{{Labeling
|area=Respiration, Pharmacology;toxicology
|area=Respiration, Pharmacology;toxicology
|diseases=Infectious
|diseases=Infectious
|organism=Mouse
|tissues=Fibroblast
|preparations=Intact cells
|couplingstates=ROUTINE, ET
|instruments=Oxygraph-2k
|instruments=Oxygraph-2k
|additional=2020-11
|additional=2020-11
}}
}}

Latest revision as of 22:40, 17 November 2020

Publications in the MiPMap
PelΓ‘ez Coyotl EA, Barrios Palacios J, MuciΓ±o G, Moreno-Blas D, Costas M, Montiel Montes T, Diener C, Uribe-Carvajal S, Massieu L, Castro-ObregΓ³n S, Espinosa OR, Mata Espinosa D, Barrios-Payan J, LeΓ³n Contreras JC, Corzo G, HernΓ‘ndez-Pando R, Del Rio G (2020) Antimicrobial peptide against Mycobacterium tuberculosis that activates autophagy is an effective treatment for tuberculosis. Pharmaceutics 12:E1071.

Β» PMID: 33182483 Open Access

Pelaez Coyotl Erika A, Barrios Palacios Jacqueline, Mucino Gabriel, Moreno-Blas Daniel, Costas Miguel, Montiel Montes Teresa, Diener Christian, Uribe-Carvajal Salvador, Massieu Lourdes, Castro-Obregon Susana, Espinosa Octavio Ramos, Mata Espinosa Dulce, Barrios-Payan Jorge, Contreras Juan Carlos Leon, Corzo Gerardo, Hernandez-Pando Rogelio, Del Rio Gabriel (2020) Pharmaceutics

Abstract: Mycobacterium tuberculosis (MTB) is the principal cause of human tuberculosis (TB), which is a serious health problem worldwide. The development of innovative therapeutic modalities to treat TB is mainly due to the emergence of multi drug resistant (MDR) TB. Autophagy is a cell-host defense process. Previous studies have reported that autophagy-activating agents eliminate intracellular MDR MTB. Thus, combining a direct antibiotic activity against circulating bacteria with autophagy activation to eliminate bacteria residing inside cells could treat MDR TB. We show that the synthetic peptide, IP-1 (KFLNRFWHWLQLKPGQPMY), induced autophagy in HEK293T cells and macrophages at a low dose (10 ΞΌM), while increasing the dose (50 ΞΌM) induced cell death; IP-1 induced the secretion of TNFΞ± in macrophages and killed Mtb at a dose where macrophages are not killed by IP-1. Moreover, IP-1 showed significant therapeutic activity in a mice model of progressive pulmonary TB. In terms of the mechanism of action, IP-1 sequesters ATP in vitro and inside living cells. Thus, IP-1 is the first antimicrobial peptide that eliminates MDR MTB infection by combining four activities: reducing ATP levels, bactericidal activity, autophagy activation, and TNFΞ± secretion. β€’ Keywords: Antimicrobial peptide, Autophagy, Iztli peptide, Multidrug resistant, Tuberculosis β€’ Bioblast editor: Plangger M β€’ O2k-Network Lab: MX Mexico City Uribe-Carvajal S


Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Infectious 

Organism: Mouse  Tissue;cell: Fibroblast  Preparation: Intact cells 


Coupling state: ROUTINE, ET 

HRR: Oxygraph-2k 

2020-11 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.